Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic.
View / Open Files
Publication Date
2022-01-20Journal Title
BMC Med Res Methodol
ISSN
1471-2288
Publisher
Springer Science and Business Media LLC
Volume
22
Issue
1
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Ewings, S., Saunders, G., Jaki, T., & Mozgunov, P. (2022). Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic.. BMC Med Res Methodol, 22 (1) https://doi.org/10.1186/s12874-022-01512-0
Abstract
BACKGROUND: Modern designs for dose-finding studies (e.g., model-based designs such as continual reassessment method) have been shown to substantially improve the ability to determine a suitable dose for efficacy testing when compared to traditional designs such as the 3 + 3 design. However, implementing such designs requires time and specialist knowledge. METHODS: We present a practical approach to developing a model-based design to help support uptake of these methods; in particular, we lay out how to derive the necessary parameters and who should input, and when, to these decisions. Designing a model-based, dose-finding trial is demonstrated using a treatment within the AGILE platform trial, a phase I/II adaptive design for novel COVID-19 treatments. RESULTS: We present discussion of the practical delivery of AGILE, covering what information was found to support principled decision making by the Safety Review Committee, and what could be contained within a statistical analysis plan. We also discuss additional challenges we encountered in the study and discuss more generally what (unplanned) adaptations may be acceptable (or not) in studies using model-based designs. CONCLUSIONS: This example demonstrates both how to design and deliver an adaptive dose-finding trial in order to support uptake of these methods.
Keywords
Phase I, Bayesian, Adaptive Design, Dose Escalation, Humans, Bayes Theorem, Maximum Tolerated Dose, Dose-Response Relationship, Drug, Research Design, Pandemics, COVID-19, SARS-CoV-2
Sponsorship
Medical Research Council (MC_UU_00002/14)
NIHR Academy (NIHRDH-SRF-2015-08-001)
Medical Research Council (MR/V028391/1)
National Institute for Health Research (NIHRDH-IS-BRC-1215-20014)
Identifiers
PMC8771176, 35057758
External DOI: https://doi.org/10.1186/s12874-022-01512-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/334290
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.